These findings identified a novel oncogenic and autophagic machinery component, GBA, as a therapeutic target in HCC and revealed a new pharmacological mechanism by which ART suppresses HCC through targeting of GBA, implying the anti-HCC potential of ART as a novel lysosomal autophagy inhibitor. The gene discussed is GBA1; the disease is hepatocellular carcinoma.